Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder
- PMID: 23001982
- PMCID: PMC6807352
- DOI: 10.1002/jcla.21532
Alterations of dendritic cell subsets and TH1/TH2 cytokines in the peripheral circulation of patients with superficial transitional cell carcinoma of the bladder
Abstract
Background: Dendritic cells (DCs) and cytokines play an important role in the tumor growth and recurrence.
Methods: Sixty-six patients with superficial transitional cell carcinoma of the bladder (STCCB) and 38 healthy controls were studied to investigate the percentages of DC subsets, monocyte-derived DC (MoDC) function, and alterations of Th1 and Th2 cytokines. MoDCs were generated and three-color flow cytometry was used for determining the phenotype of MoDCs and DC subsets. The ability to stimulate autologous T cells was tested in mixed leukocyte reaction (MLR). The levels of various cytokines were measured using commercially available sandwich enzyme linked immunosorbent assay (ELISA) kit.
Results: The myeloid DC (mDC) counts, MoDC surface molecular expression, and stimulatory capacity to T cells were impaired in STCCB patients than in controls. The percentage of mDC and the expression of CD80, CD83, and CD86 were lower in patients showing recurrence. The serum levels of IL-2 and IFN-γ were found to be significantly lower while IL-4, IL-6, and IL-10 were significantly higher in STCCB patients than in controls. IL-6 was found to be significantly higher in recurrent patients.
Conclusion: The impairment of mDC counts and MoDC function with imbalance of Th1/Th2 cytokines was closely associated with proliferation and recurrence of STCCB.
© 2012 Wiley Periodicals, Inc.
Figures


Similar articles
-
Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder.Cancer Immunol Immunother. 2006 Jun;55(6):734-43. doi: 10.1007/s00262-005-0045-2. Epub 2005 Nov 10. Cancer Immunol Immunother. 2006. PMID: 16283306 Free PMC article.
-
Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy.Immunopharmacol Immunotoxicol. 2010 Jun;32(2):348-56. doi: 10.3109/08923970903300151. Immunopharmacol Immunotoxicol. 2010. PMID: 20105083 Clinical Trial.
-
Therapeutic influence on circulating and monocyte-derived dendritic cells in laryngeal squamous cell carcinoma patients.Acta Otolaryngol. 2009 Jan;129(1):84-91. doi: 10.1080/00016480802020459. Acta Otolaryngol. 2009. PMID: 18607895
-
Distinct dendritic cell subsets actively induce Th2 polarization.Curr Opin Immunol. 2014 Dec;31:44-50. doi: 10.1016/j.coi.2014.09.006. Epub 2014 Oct 4. Curr Opin Immunol. 2014. PMID: 25290173 Free PMC article. Review.
-
Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement.J Dermatol Sci. 2006 Apr;42(1):1-11. doi: 10.1016/j.jdermsci.2005.11.004. Epub 2005 Dec 13. J Dermatol Sci. 2006. PMID: 16352421 Review.
Cited by
-
Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.Oncotarget. 2016 Jun 28;7(26):39916-39930. doi: 10.18632/oncotarget.9537. Oncotarget. 2016. PMID: 27221038 Free PMC article.
-
High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.Oncol Lett. 2018 May;15(5):6519-6526. doi: 10.3892/ol.2018.8173. Epub 2018 Mar 5. Oncol Lett. 2018. PMID: 29725402 Free PMC article.
-
The inflammatory microenvironment and the urinary microbiome in the initiation and progression of bladder cancer.Genes Dis. 2020 Oct 13;8(6):781-797. doi: 10.1016/j.gendis.2020.10.002. eCollection 2021 Nov. Genes Dis. 2020. PMID: 34522708 Free PMC article. Review.
-
Nonsense-Mediated Decay Targeted RNA (ntRNA): Proposal of a ntRNA-miRNA-lncRNA Triple Regulatory Network Usable as Biomarker of Prognostic Risk in Patients with Kidney Cancer.Genes (Basel). 2022 Sep 15;13(9):1656. doi: 10.3390/genes13091656. Genes (Basel). 2022. PMID: 36140823 Free PMC article.
-
A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study.BMC Cancer. 2022 Mar 23;22(1):311. doi: 10.1186/s12885-022-09433-3. BMC Cancer. 2022. PMID: 35321670 Free PMC article.
References
-
- Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:475–477. - PubMed
-
- Akagashi K, Tanda H, Kato S, et al. Recurrence pattern for superficial bladder cancer. Int J Urol 2006;13:686–691. - PubMed
-
- Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol 2006;24(5):565–578. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical